Investigating genetic factors affecting diabetes treatment response
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
This study is trying to see how genetic differences affect how well the diabetes drug exenatide works for Chinese patients with Type 2 Diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 25 Years to 70 Years |
| Sex | All |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University Academic / other |
| Locations | 1 site (Xuzhou, China) |
| Trial ID | NCT06256419 on ClinicalTrials.gov |
What this trial studies
This study examines how genetic variations influence the effectiveness of exenatide, a GLP-1 receptor agonist, in treating Type 2 Diabetes Mellitus (T2DM) among Chinese patients. It involves a retrospective cohort of patients who have been treated with exenatide for at least 12 months, analyzing various gene polymorphisms associated with T2DM susceptibility. The goal is to identify predictors of treatment efficacy and understand the genetic determinants that contribute to individual differences in response to antidiabetic medications. This research aims to enhance personalized treatment strategies for T2DM patients based on their genetic profiles.
Who should consider this trial
Good fit: Ideal candidates include Chinese patients aged 25-70 with a diagnosis of T2DM and specific BMI and HbA1c levels.
Not a fit: Patients with serious comorbidities or those who have recently used certain medications affecting gastrointestinal function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment plans for patients with Type 2 Diabetes Mellitus.
How similar studies have performed: Other studies have shown promise in using genetic factors to predict treatment responses in diabetes, suggesting this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. a diagnosis of T2DM 2. a body mass index (BMI) of 20-35 kg/m2 3. an HbA1c of 7.0%-12%, an age of 25-70 years 4. required data available at baseline and 6 months after GLP-1RA therapy. Exclusion Criteria: 1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis 2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months 3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.
Where this trial is running
Xuzhou, China
- China, Jiangsu, Department of Endocrinology — Xuzhou, China, China (Recruiting)
Study contacts
- Study coordinator: Tao Wang, Ph.D
- Email: misswt2011@126.com
- Phone: 13815344640
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.